vs

Side-by-side financial comparison of CARTERS INC (CRI) and Charles River Laboratories (CRL). Click either name above to swap in a different company.

Charles River Laboratories is the larger business by last-quarter revenue ($994.2M vs $757.8M, roughly 1.3× CARTERS INC). CARTERS INC runs the higher net margin — 1.5% vs -27.8%, a 29.3% gap on every dollar of revenue. On growth, CARTERS INC posted the faster year-over-year revenue change (-0.1% vs -0.8%). Charles River Laboratories produced more free cash flow last quarter ($58.6M vs $-144.1M).

Carter's, Inc. is a major American designer and marketer of children's apparel. It was founded in 1865 by William Carter.

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.

CRI vs CRL — Head-to-Head

Bigger by revenue
CRL
CRL
1.3× larger
CRL
$994.2M
$757.8M
CRI
Growing faster (revenue YoY)
CRI
CRI
+0.7% gap
CRI
-0.1%
-0.8%
CRL
Higher net margin
CRI
CRI
29.3% more per $
CRI
1.5%
-27.8%
CRL
More free cash flow
CRL
CRL
$202.7M more FCF
CRL
$58.6M
$-144.1M
CRI

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
CRI
CRI
CRL
CRL
Revenue
$757.8M
$994.2M
Net Profit
$11.6M
$-276.6M
Gross Margin
45.1%
Operating Margin
3.8%
-28.5%
Net Margin
1.5%
-27.8%
Revenue YoY
-0.1%
-0.8%
Net Profit YoY
-80.1%
-28.9%
EPS (diluted)
$0.32
$-5.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRI
CRI
CRL
CRL
Q4 25
$994.2M
Q3 25
$757.8M
$1.0B
Q2 25
$585.3M
$1.0B
Q1 25
$629.8M
$984.2M
Q4 24
$1.0B
Q3 24
$1.0B
Q2 24
$1.0B
Q1 24
$1.0B
Net Profit
CRI
CRI
CRL
CRL
Q4 25
$-276.6M
Q3 25
$11.6M
$54.4M
Q2 25
$446.0K
$52.3M
Q1 25
$15.5M
$25.5M
Q4 24
$-214.5M
Q3 24
$69.7M
Q2 24
$94.1M
Q1 24
$73.0M
Gross Margin
CRI
CRI
CRL
CRL
Q4 25
Q3 25
45.1%
Q2 25
48.1%
Q1 25
46.2%
Q4 24
Q3 24
34.6%
Q2 24
34.5%
Q1 24
34.1%
Operating Margin
CRI
CRI
CRL
CRL
Q4 25
-28.5%
Q3 25
3.8%
13.3%
Q2 25
0.7%
9.7%
Q1 25
4.1%
7.6%
Q4 24
-16.7%
Q3 24
11.6%
Q2 24
14.8%
Q1 24
12.5%
Net Margin
CRI
CRI
CRL
CRL
Q4 25
-27.8%
Q3 25
1.5%
5.4%
Q2 25
0.1%
5.1%
Q1 25
2.5%
2.6%
Q4 24
-21.4%
Q3 24
6.9%
Q2 24
9.2%
Q1 24
7.2%
EPS (diluted)
CRI
CRI
CRL
CRL
Q4 25
$-5.57
Q3 25
$0.32
$1.10
Q2 25
$0.01
$1.06
Q1 25
$0.43
$0.50
Q4 24
$-4.17
Q3 24
$1.33
Q2 24
$1.74
Q1 24
$1.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRI
CRI
CRL
CRL
Cash + ST InvestmentsLiquidity on hand
$184.2M
$213.8M
Total DebtLower is stronger
$2.1B
Stockholders' EquityBook value
$864.6M
$3.2B
Total Assets
$2.5B
$7.1B
Debt / EquityLower = less leverage
0.68×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRI
CRI
CRL
CRL
Q4 25
$213.8M
Q3 25
$184.2M
$207.1M
Q2 25
$338.2M
$182.8M
Q1 25
$320.8M
$229.4M
Q4 24
$194.6M
Q3 24
$210.2M
Q2 24
$179.2M
Q1 24
$327.0M
Total Debt
CRI
CRI
CRL
CRL
Q4 25
$2.1B
Q3 25
$2.2B
Q2 25
$2.3B
Q1 25
$2.5B
Q4 24
$2.2B
Q3 24
$2.3B
Q2 24
$2.4B
Q1 24
$2.7B
Stockholders' Equity
CRI
CRI
CRL
CRL
Q4 25
$3.2B
Q3 25
$864.6M
$3.4B
Q2 25
$853.9M
$3.4B
Q1 25
$847.2M
$3.2B
Q4 24
$3.5B
Q3 24
$3.8B
Q2 24
$3.7B
Q1 24
$3.6B
Total Assets
CRI
CRI
CRL
CRL
Q4 25
$7.1B
Q3 25
$2.5B
$7.5B
Q2 25
$2.5B
$7.6B
Q1 25
$2.3B
$7.6B
Q4 24
$7.5B
Q3 24
$8.0B
Q2 24
$7.9B
Q1 24
$8.2B
Debt / Equity
CRI
CRI
CRL
CRL
Q4 25
0.68×
Q3 25
0.64×
Q2 25
0.70×
Q1 25
0.79×
Q4 24
0.65×
Q3 24
0.62×
Q2 24
0.65×
Q1 24
0.73×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRI
CRI
CRL
CRL
Operating Cash FlowLast quarter
$-128.0M
$147.5M
Free Cash FlowOCF − Capex
$-144.1M
$58.6M
FCF MarginFCF / Revenue
-19.0%
5.9%
Capex IntensityCapex / Revenue
2.1%
8.9%
Cash ConversionOCF / Net Profit
-11.04×
TTM Free Cash FlowTrailing 4 quarters
$518.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRI
CRI
CRL
CRL
Q4 25
$147.5M
Q3 25
$-128.0M
$213.8M
Q2 25
$40.3M
$204.6M
Q1 25
$-48.6M
$171.7M
Q4 24
$159.4M
Q3 24
$251.8M
Q2 24
$193.5M
Q1 24
$129.9M
Free Cash Flow
CRI
CRI
CRL
CRL
Q4 25
$58.6M
Q3 25
$-144.1M
$178.2M
Q2 25
$24.1M
$169.3M
Q1 25
$-59.0M
$112.4M
Q4 24
$83.7M
Q3 24
$213.1M
Q2 24
$154.0M
Q1 24
$50.7M
FCF Margin
CRI
CRI
CRL
CRL
Q4 25
5.9%
Q3 25
-19.0%
17.7%
Q2 25
4.1%
16.4%
Q1 25
-9.4%
11.4%
Q4 24
8.4%
Q3 24
21.1%
Q2 24
15.0%
Q1 24
5.0%
Capex Intensity
CRI
CRI
CRL
CRL
Q4 25
8.9%
Q3 25
2.1%
3.5%
Q2 25
2.8%
3.4%
Q1 25
1.6%
6.0%
Q4 24
7.5%
Q3 24
3.8%
Q2 24
3.8%
Q1 24
7.8%
Cash Conversion
CRI
CRI
CRL
CRL
Q4 25
Q3 25
-11.04×
3.93×
Q2 25
90.37×
3.91×
Q1 25
-3.13×
6.74×
Q4 24
Q3 24
3.61×
Q2 24
2.06×
Q1 24
1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRI
CRI

Sales Channel Directly To Consumer$362.3M48%
Sales Channel Through Intermediary$283.8M37%
Other$110.4M15%
Gift Cards$1.3M0%

CRL
CRL

Discovery And Safety Assessment Segment$591.6M60%
Manufacturing Support Segment$196.4M20%
Transferred At Point In Time$108.0M11%
Transferred Over Time$98.3M10%

Related Comparisons